Pharmaceutical Approval Update May 2019 - P&T Community

Submitted by Anonymous (not verified) on Wed, 05/01/2019 - 09:57

Pharmaceutical Approval Update May 2019  P&T CommunityCablivi (caplacizumab-yhdp) for acquired thrombotic thrombocytopenic purpura; Egaten (triclabendazole) for fascioliasis; and Spravato (esketamine) for ...